Regis Technologies gains significant efficiencies in pharma/biopharma manufacturing

Importance of the Topic

In high-volume pharmaceutical and biopharmaceutical manufacturing, robust and efficient chromatography data management is essential to accelerate drug development, ensure consistent product quality, and maintain regulatory compliance. Integrating advanced chromatography data system (CDS) software into contract manufacturing workflows can reduce manual intervention, minimize errors, and support full audit trails.

Objectives and Overview of the Study

This case study describes how Regis Technologies, a Chicago-based contract management organization (CMO) specializing in API synthesis and purification, selected and implemented Thermo Scientific Chromeleon 7.1 CDS. The primary aims were to evaluate system suitability, peak integration, and reporting features; streamline QC analyses across liquid and gas chromatography platforms; and quantify efficiency gains in a two-shift operation.

Methodology and Instrumentation

Regis Technologies conducted a three-phase deployment over four weeks, covering instrument conversion, user training, and method validation under 21 CFR requirements. Key implementation steps included:

• Phase 1: Converting half of the QC instruments to Chromeleon and delivering a four-day procedural training.
• Phase 2: Transitioning the remaining instruments.
• Phase 3: Onboarding process research and development groups, including supercritical fluid chromatography (SFC).
• Week 4: Performing qualification and validation by Quality Assurance to confirm regulatory compliance.

Used Instrumentation

Chromatography systems integrated into Chromeleon 7.1 included 14 high-performance liquid chromatography (HPLC) units and 6 gas chromatography (GC) units. Plans are under way to capture data from additional platforms such as FTIR, UV-VIS, NMR, and a new Thermo Scientific TRACE 1310 GC system.

Main Results and Discussion

After full deployment, all 20 analysts and 5 QA reviewers achieved proficiency within one week of installation, with ongoing user-level training. Over 800 test methods and 300 validated methods are managed across multiple Chromeleon Data Vaults, providing distinct access privileges and 21 CFR validation. Approximately 30 test methods and 20 validated methods have been converted to Chromeleon so far, with conversion efforts continuing as new methods emerge.

Benefits and Practical Applications

The integration of Chromeleon CDS delivered measurable gains:

• Peak integration consistency via Cobra Wizard, reducing manual tuning and ensuring reliable area, height, and retention time calculations.
• Automated system suitability testing (SST), allowing unattended runs and automated pass/fail decisions that reclaimed an entire shift previously lost to manual monitoring.
• Report Designer Pro consolidated data acquisition, processing, and formatting into a single electronic report with locked-down templates, cutting report generation time from 2–3 hours to under 1 hour.
• MiniPlot visualization enabled rapid review of dozens of injections in thumbnail view, facilitating fast data assessment.

Future Trends and Opportunities

Regis Technologies plans to leverage Chromeleon’s tracking and trending templates to monitor readiness criteria such as peak area, retention time, and column efficiency in real time. Expansion to non-chromatographic data capture (e.g., FTIR, NMR) and integration of newly released CDS features are expected to further streamline operations. Annual upgrades and process improvements will continue to align the system with evolving regulatory and manufacturing demands.

Conclusion

The implementation of Thermo Scientific Chromeleon 7.1 CDS at Regis Technologies demonstrates how advanced CDS capabilities can enhance analytical QC efficiency, improve data integrity, and support regulatory compliance in a high-throughput CMO environment. The system’s integration tools, automated SST, and flexible reporting deliver significant time savings and robust data management, positioning the lab for scalable growth and future technological integration.